Современные представления об идеальной комбинации антигипертензивных препаратов для профилактики инсульта

1. Смертность населения Российской Федерации, 1998 г. (статистические материалы). М.: Минздрав РФ, 2006.
2. Гусев Е.И., Скворцова В.И., Стаховская Л.В. Проблема инсульта в Российской Федерации: время активных совместных действий. Журн. неврологии и психиатрии. 2007; 8: 4–10.
3. Диагностика и лечение артериальной гипертензии. Системные гипертензии. 2010; 3: 5–26.
4. Lewington S, Clarke R, Qizilbash N et al. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–13.
5. Staessen JA, Wang J-G, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21: 1055–76.
6. Reboldi G, Angeli F, Cavallini C et al. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens 2008; 26 (7): 1282–9.
7. Dahlöf B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE). Lancet 2002; 359: 995–1003.
8. Dahlöf B, Devereux RB, de Faire U et al. The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study. Am J Hypertens 1997; 10: 705–13.
9. Verdecchia P Porcellati C, Reboldi G et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation 2001; 104: 2039–44.
10. Верещагин Н.В. Гетерогенность инсульта в клинической практике. Атмосфера. Нервные болезни. 2004; 1: 19–20.
11. Dempsey RJ, Diana AL, Moore RW. Thickness of carotid artery atherosclerotic plaque and ischemic risk. Neurosurgery 1990; 27 (3): 343–8.
12. Olsen MH, Wachtell K, Neland K et al. Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy. Blood Press 2005; 14: 177–83.
13. Sonoda M, Aoyagi T, Takenaka K et al. A One-Year Study of the Antiatherosclerotic Effect of the Angiotensin-II Receptor Blocker Losartan in Hypertensive Patients (A Comparison With Angiotensin-Converting Enzyme Inhibitors). Int Heart J 2008; 49 (1): 95–103.
14. Strawn WB, Chappell MC, Dean RH et al. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 2000; 101: 1586–93.
15. Schiffrin EL, Park JB, Intengan HD et al. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101: 1653–9.
16. Prasad A, Tupas-Habib T, Schenke WH et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation 2000; 101: 2349–54.
17. Cheetham C, Collis J, O’Driscoll G et al. Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes. J Am Coll Cardiol 2000; 36 (5): 1461–6.
18. Hornig B, Landmesser U, Kohler C et al. Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: Role of superoxide dismutase. Circulation 2001; 103: 799–805.
19. Guerra-Cuesta JI, Montón M, Rodriguez-Feo JA et al. Effect of losartan on human platelet activation. J Hypertens 1999; 17: 447–52.
20. Erdem Y, Usalan C, Haznedaroğlu IC et al. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens 1999; 11: 1071–6.
21. Levy PJ, Yunis C, Owen J et al. Inhibition of platelet aggregability by losartan in essential hypertension. Am J Cardiol 2000; 86: 1188–92.
22. Fogari R, Zoppi A, Malamani G et al. Effects of four angiotensin II-receptor antagonists on fibrinolysis in postmenopausal women with hypertension. Curr Ther Res Clin Exp 2001; 62: 68–78.
23. Krämer C, Sunkomat J, Witte J et al. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: Role of the active metabolite EXP3179. Circ Res 2002; 90: 770–6.
24. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983–8.
25. Wachtell K, Lehto M, Gerdts E et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The LIFE Study. J Am Coll Cardiol 2005; 45: 712–9.
26. Devereux RB, Bella J, Boman K et al. Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. Blood Press 2001; 10: 74–82.
27. Wachtell K, Hornestam B, Lehto M et al. Cardiovascular morbidity and mortality in hypertensive patients with atrial fibrillation: The LIFE study. J Am Coll Cardiol 2005; 45: 705–11.
28. Olsen MH, Wachtell K, Bella JN et al. Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a Losartan Intervention For Endpoint reduction in hypertension (LIFE) substudy. Am J Hypertens 2005; 18: 1430–6.
29. Ibsen H, Wachtell K, Olsen MH et al., for the LIFE Substudy. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens 2004; 22: 1805–11.
30. Kobel F, Gregorova I, Sonka J. Hyperuricaemia in hypertension. Lancet 1965; 1: 519–20.
31. Kinsey D, Walther R, Sise HS et al. Incidence of hyperuricaemia in 400 hypertensive patients. Circulation 1961; 24: 972–3.
32. France LV, Pahor M, Di Bari M et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000; 18: 1149–54.
33. Hoieggen A, Alderman MH, Kjeldsen SE et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041–9.
34. Sweet CS, Bradstreet DC, Berman RS et al. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am J Hypertens 1994; 7 (12): 1035–40.
35. Burnier M, Hagmann M, Nussberger I et al. Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 1995; 25 (4p 1): 602–9.
36. Shahinfar S, Simpson R, Carides A et al. Safety of losartan in hypertensive patients with asymptomatic hyperuricemia. JASN 1997; 8: 322.
37. Pitt B, Byington RP, Furberg CD et al. Effect of amlodipine on progression of atherosclerosis and the occurrence of clinical events. PREVENT investigators. Circulation 2000; 102 (13): 1503–10.
38. Webb AJS, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in BP and risk of stroke: a systematic review and meta-analysis. Lancet 2010; 375: 906–15.
39. Rothwell PM, Webb AJS. Effect of Dose and Combination of Antihypertensives on Interindividual Blood Pressure Variability: A Systematic Review. Stroke 2011; 42: 2860–5.
40. Rothwell PM, Howard SC, Dolan E et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375: 895–905.

О.Д.Остроумова*1,2, В.М.Фомина1, Т.Ф.Гусева1

1 Кафедра факультетской терапии и профболезней ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России
2 ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России
*ostroumova.olga@mail.ru

________________________________________________

O.D.Ostroumova*, V.M.Fomina, T.F.Guseva
*ostroumova.olga@mail.ru